Tumours use various strategies to evade immune surveillance,. Immunotherapies targeting
tumour immune evasion such as immune checkpoint blockade have shown considerable …

Epigenetic silencing including histone modifications and DNA methylation is an important
tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy …

Glioblastoma (GBM) tumors are enriched in immune-suppressive myeloid cells and are
refractory to immune checkpoint therapy (ICT). Targeting epigenetic pathways to reprogram …

Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to
subvert T-cell-mediated immunosurveillance,. The success of therapies that disrupt PD-L1 …

Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune
escape,. Here, to identify factors that modulate the immune sensitivity of cancer cells, we …

Immune checkpoint blockade (ICB) therapies are now established as first-line treatments for
multiple cancers, but many patients do not derive long-term benefit from ICB. Here, we report …

Constitutive expression of the immune checkpoint, PD-L1, inhibits anti-tumor immune
responses in cancer, although the factors involved in PD-L1 regulation are poorly …

Cyclic GMP-AMP (cGAMP) synthase (cGAS) stimulator of interferon genes (STING) senses
pathogen-derived or abnormal self-DNA in the cytosol and triggers an innate immune …

Developing strategies to activate tumor-cell-intrinsic immune response is critical for
improving tumor immunotherapy by exploiting tumor vulnerability. KDM4A, as a histone H3 …

The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations
in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in …